FDA Proposes to Eliminate "Adequate Provision" for Broadcast Prescription Drug Advertising - foleyhoag.com
FDA proposes to eliminate the 'adequate provision' requirement for broadcast prescription drug advertising, which currently mandates that drug ads include a brief summary of risks and provide a toll-free number or website for more information. This change could affect how drug manufacturers communicate risks in TV and radio ads.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug manufacturers and any pharmaceutical companies that advertise prescription drugs via broadcast media (TV, radio). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified; proposal stage, so no immediate deadline.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA is proposing to remove the 'adequate provision' requirement, which currently requires broadcast ads to include a brief summary of risks and a mechanism (e.g., toll-free number, website) for consumers to access full prescribing information.
Who it affects
Branded drug manufacturers and any pharmaceutical companies that advertise prescription drugs via broadcast media (TV, radio).
What you must do
Monitor FDA rulemaking progress and prepare to adjust broadcast advertising strategies if the proposal is finalized. No immediate action is required until the rule is published.
Deadline
Not specified; proposal stage, so no immediate deadline.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Supreme Court Temporarily Blocks Ruling Barring Telehealth And Pharmacy Access To Mifepristone - Health Affairs
- FDA Warning Letter Cites Significant CGMP Violations at Tom’s of Maine Factory - Happi | Household And Personal Products Industry
- Connecticut Law Imposes New Requirements on Pharmaceutical Manufacturers, Defined to Include Device and Cosmetic Manufacturers, that Employ “Pharmaceutical Sales Representatives” - mintz.com
- FDA Issues Warning to Sanofi About API CGMP Deviations, Puts Clinical Hold on Atara Immunotherapies - biopharminternational.com
- Fourth Circuit Holds cGMP Violations Do Not Create False Claims Under Medicare and Medicaid - wilmerhale.com